Hims & Hers stock: growth momentum versus margin pressure and a 20.6% fair value discount

JPMorgan initiated coverage of Hims & Hers Health with a Neutral rating and a $32 price target for 2027. The firm acknowledges the company's growth but highlights risks in its transition to branded weight-loss drugs. Hims has 2.9 million subscribers and a partnership with Novo Nordisk for Wegovy shipments. JPMorgan projects 2026 GLP-1 revenue of $1.1 billion and long-term revenue growth to over $6.5 billion by 2030, but cautions on execution risks.

Hims & Hers Health (HIMS) faces regulatory scrutiny from the FDA and FTC, causing volatility and analyst caution. The company's AI-driven growth strategy and data-driven patient care are seen as long-term differentiators. Recent insider trading shows 24 sales and 1 purchase. Q2 2026 revenue grew 38.25% to $753.2M. Analysts' price targets range from $23 to $40.

Hims & Hers Health (HIMS) faces an FTC lawsuit and class action over alleged data sharing and billing practices, which could impact customer trust and its telehealth model. Analysts project revenues of $4.6B and earnings of $241M by 2029, with a fair value estimate of $31.23. The company is also expanding into Australia, adding regulatory complexity. Some analysts have more pessimistic forecasts due to data privacy risks.

Hims & Hers Health Inc. (HIMS) shares fell 1% overnight after the FDA issued warnings to 30 telehealth firms, including HIMS, over misleading marketing claims about GLP-1 weight-loss drugs. HIMS stock has dropped over 50% this year. The FDA cited false claims about compounded Semaglutide, Tirzepatide, and Liraglutide. Despite the warning, some traders see the issue as a marketing problem, not a fundamental threat, and highlight HIMS's potential in peptides and telehealth services.

Robinhood Chain, a Layer-2 blockchain, launched with tokenized U.S. equities (Stock Tokens) backed 1-to-1 by real shares. A new trading strategy involves pairing meme coins with these Stock Tokens, creating demand and volatility. For example, BONER meme coin trading caused tokenized HIMS to surge 112% over the weekend due to supply constraints. AMC CEO Adam Aron criticized the use of AMC Stock Tokens, while Robinhood defended its position. This highlights the potential for significant price swin

Hims & Hers Health (HIMS) shares fell 0.3% overnight after FDA staff raised safety concerns about seven popular peptides, potentially impacting a regulatory opportunity. The FDA staff's views contrast with Health Secretary Robert F. Kennedy Jr.'s push to deregulate peptides. HIMS has invested in peptide manufacturing, with analysts seeing potential for a new revenue stream. Analyst Ryan MacDonald believes approval odds remain, despite the recent setback.